

# **Keros Therapeutics Inc.**

Fact Sheet

# **K R O S**

**L I S T E D**

# **N A S D A Q**

**INITIAL PUBLIC OFFERING <> APRIL 2020**

# Keros Therapeutics

## QUICK REFERENCE

Keros Therapeutics Inc.

Nasdaq: **KROS**

Outstanding Shares: **2,484,057** (as of March 31, 2020)

Website: [www.KEROSTX.com](http://www.KEROSTX.com)

## BUSINESS SUMMARY

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematologic and musculoskeletal disorders with a high unmet medical need. Keros is a leader in understanding the role of the Transforming Growth Factor-Beta, or TGF- $\beta$ , family of proteins, which are master regulators of red blood cell and platelet production as well as of the growth, repair and maintenance of muscle and bone. Keros' lead protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes and in patients with myelofibrosis. Keros' lead small molecule product candidate, KER-047, is being developed for the treatment of anemia resulting from elevated levels of hepcidin, the key regulator of iron absorption and recycling, as well as for the treatment of fibrodysplasia ossificans progressiva. Keros' third product candidate, KER-012, is being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension.

## IPO

Initial Public Offering of 6,900,000 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 900,000 additional shares, at a public offering price of \$16.00 per share, for total gross proceeds of \$110.4 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares of common stock were sold by Keros.

Keros' common stock began trading on the Nasdaq Global Market on April 8, 2020 under the symbol "KROS".

Jefferies LLC, SVB Leerink LLC and Piper Sandler & Co. acted as joint book-running managers for the offering. H.C. Wainwright & Co., LLC acted as co-manager for the offering.

## CONTACT INFORMATION

US Headquarters

99 Hayden Avenue

Lexington, MA 02421

Andrew Barwicki

516-662-9461/[andrew@barwicki.com](mailto:andrew@barwicki.com)

# Keros Therapeutics, Inc. <> KROS

## Recent Press Releases *(Headlines and Excerpts)*

### **Keros Therapeutics Presents Results from Clinical and Preclinical Studies Investigating KER-050, along with Preclinical Data from its ALK2 Inhibitor Program, at the European Hematology Association 2020 Annual Meeting**

- Poster presentation highlights Phase 1 clinical trial data demonstrating tolerability, pharmacokinetics and pharmacodynamics of KER-050 in healthy postmenopausal women.
- Poster presentations introduce data demonstrating KER-050 robustly promoted hematopoiesis in multiple animal species in preclinical studies and support a potentially novel mechanism of action.
- Oral presentation on a novel ALK2 kinase inhibitor that suppressed hepcidin production and subsequently ameliorated anemia in a mouse model of iron-refractory iron deficiency anemia.

June 12, 2020 -- Keros Therapeutics, Inc. announced updated data from its Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamic effects of ascending dose levels of KER-050 in healthy post-menopausal women, along with preclinical data on KER-050 from multiple animal models and additional preclinical data evaluating the role of ALK2 inhibition in regulating hepcidin and serum iron.

### **Keros Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results**

May 22, 2020 -- Keros Therapeutics, Inc. today provided a business update and reported financial results for the first quarter of 2020.

#### Recent Program Highlights:

- KER-050 for the treatment of ineffective hematopoiesis to address cytopenias: In January 2020, Keros completed a randomized, double-blind, placebo-controlled, two-part, dose-escalation Phase 1 clinical trial of KER-050 in 48 healthy post-menopausal women. Keros plans to report the positive topline data from this trial at the virtual 25th Congress of the European Hematology Association (EHA) taking place June 11-14 2020. In addition, two abstracts outlining data from preclinical studies of KER-050 in multiple animal models have been accepted for presentation at the 25th Congress of the EHA taking place from June 11 to 14, 2020. Commencement of an open-label Phase 2 clinical trial of KER-050 evaluating the treatment of cytopenias, including anemia and thrombocytopenia, in patients with very low-, low- or intermediate-risk myelodysplastic syndromes is expected in the second half of 2020, subject to any delays related to the COVID-19 pandemic.
- KER-047 for the treatment of anemia arising from high hepcidin levels and for the treatment of fibrodysplasia ossificans progressiva: Keros expects to complete its Phase 1 clinical trial of KER-047 in mid-2020, and to subsequently report data from this trial in the second half of 2020, subject to any delays related to the COVID-19 pandemic.
- KER-012 for the treatment of disorders associated with bone loss and for the treatment of pulmonary arterial hypertension Keros has selected KER-012 as a product candidate for further preclinical and clinical development.

Standard Mail  
U.S. Postage Paid  
Garden City, NY  
Permit No. 431

# **Keros Therapeutics, Inc.**

## **Nasdaq: KROS**

## **WWW.KEROSTX.COM**

---

Barwicki Investor Relations \* 30 Wall Street, 8 FL \* New York, NY 10005

Deliver to: